Tirabrutinib

Name: Tirabrutinib in Primary central nervous system lymphoma: Humanistic burden and health-related quality of life
Published: 2026-09-14T15:39:06-04:00

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Primary central nervous system lymphoma

Humanistic burden and health-related quality of life

1 evidence topic · 1 source

Long-term survivors: neuroimaging and quality of life after whole-brain radiotherapy

“Total T2 abnormalities after WBRT were more than twice the mean of any non-WBRT group and were associated with poorer neuropsychological and QOL outcomes.” (opens the source at this quote in a new tab)